Artículos de revistas
The Iron Chelator Pyridoxal Isonicotinoyl Hydrazone Inhibits Mitochondrial Lipid Peroxidation Induced By Fe(ii)-citrate
Registro en:
European Journal Of Pharmacology. , v. 428, n. 1, p. 37 - 44, 2001.
142999
10.1016/S0014-2999(01)01291-2
2-s2.0-0035964737
Autor
Santos N.C.F
Castilho R.F.
Meinicke A.R.
Hermes-Lima M.
Institución
Resumen
Pyridoxal isonicotinoyl hydrazone (PIH) is able to prevent iron-mediated hydroxyl radical formation by means of iron chelation and inhibition of redox cycling of the metal. In this study, we investigated the effect of PIH on Fe(II)-citrate-mediated lipid peroxidation and damage to isolated rat liver mitochondria. Lipid peroxidation was quantified by the production of thiobarbituric acid-reactive substances (TBARS) and by antimycin A-insensitive oxygen consumption. PIH at 300 μM induced full protection against 50 μM Fe(II)-citrate-induced loss of mitochondrial transmembrane potential (Δψ) and mitochondrial swelling. In addition, PIH prevented the Fe(II)-citrate-dependent formation of TBARS and antimycin A-insensitive oxygen consumption. The antioxidant effectiveness of 100 μM PIH (on TBARS formation and mitochondrial swelling) was greater in the presence of 20 or 50 μM Fe(II)-citrate than in the presence of 100 μM Fe(II)-citrate, suggesting that the mechanism of PIH antioxidant action is linked with its Fe(II) chelating property. Finally, PIH increased the rate of Fe(II) autoxidation by sequestering iron from the Fe(II)-citrate complex, forming a Fe(III)-PIH 2 complex that does not participate in Fenton-type reactions and lipid peroxidation. These results are of pharmacological relevance since PIH is a potential candidate for chelation therapy in diseases related to abnormal intracellular iron distribution and/or iron overload. © 2001 Elsevier Science B.V. All rights reserved. 428 1 37 44 Bhattacharya, M., Ponka, P., Hardy, P., Hanna, N., Varma, D.R., Lachapelle, P., Chemtob, S., Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone (1997) Free Radical Biol. Med., 22, pp. 11-16 Bindoli, A., Lipid peroxidation in mitochondria (1988) Free Radical Biol. Med., 5, pp. 247-261 Britton, R.S., Bacon, B.R., Tavill, A.S., Mechanisms of iron toxicity (1994) Iron Metabolism in Health and Disease, pp. 311-351. , Brock, J.H., Halliday, J.W., Pippard, M.J., Powell, L.W. (Eds.). W.B. Saunders, London Cadenas, E., Sies, H., The lag phase (1998) Free Radical. Res., 28, pp. 601-609 Cardoso, S.M., Pereira, C., Oliveira, C.R., Mitochondrial function is differentially affected upon oxidative stress (1999) Free Radical Biol. Med., 26, pp. 3-13 Carini, R., Parola, M., Dianzani, M.U., Albano, E., Mitochondrial damage and its role in causing hepatocyte injury during stimulation of lipid peroxidation by iron nitriloacetate (1992) Arch. Biochem. Biophys., 297, pp. 110-118 Castilho, R.F., Meinicke, A.R., Almeida, A.M., Hermes-Lima, M., Vercesi, A.E., Oxidative damage of mitochondria induced by Fe(II)-citrate is potentiated by Ca 2+ and includes lipid peroxidation and alterations in membrane proteins (1994) Arch. Biochem. Biophys., 308, pp. 158-163 Castilho, R.F., Meinicke, A.R., Vercesi, A.E., Hermes-Lima, M., The role of Fe(III) in Fe(II)-citrate-mediated peroxidation of mitochondrial membrane lipids (1999) Mol. Cell. Biochem., 196, pp. 163-168 Friberg, H., Ferrand-Drake, M., Bengtsson, F., Halestrap, A.P., Wieloch, T., Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death (1998) J. Neurosci., 18, pp. 5151-5159 Gassen, M., Youdim, M.B.H., The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders (1997) Pharmacol. Toxicol., 80, pp. 159-166 Gordon, N., Friedreich's ataxia and iron metabolism (2000) Brain Dev., 22, pp. 465-468 Green, D.R., Reed, J.C., Mitochondria and apoptosis (1998) Science, 281, pp. 1309-1312 Halliwell, B., Gutteridge, J.M.C., Antioxidant defences (1999) Free Radical in Biology and Medicine. 3rd edn., pp. 105-245. , Halliwell, B., Gutteridge, J.M.C. (Eds.). Oxford Univ. Press, Oxford, UK Hermes-Lima, M., How do Ca 2+ and 5-aminolulinic acid-derived oxyradicals promote injury to isolated mitochondria? (1995) Free Radical Biol. Med., 19, pp. 381-390 Hermes-Lima, M., Wang, E.M., Schulman, H.M., Storey, K.B., Ponka, P., Deoxyribose degradation catalyzed by Fe(III)EDTA: Kinetic aspects and potential usefulness for submicromolar iron measurements (1994) Mol. Cell. Biochem., 137, pp. 65-73 Hermes-Lima, M., Castilho, R.F., Meinicke, A.R., Vercesi, A.E., Characteristics of Fe(II)ATP complex-induced damage to the rat liver mitochondria (1995) Mol. Cell. Biochem., 145, pp. 53-60 Hermes-Lima, M., Nagy, E., Ponka, P., Schulman, H.M., The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against •OH-mediated strand breaks (1998) Free Radical Biol. Med., 25, pp. 875-880 Hermes-Lima, M., Santos, N.C.F., Yan, J., Andrews, M., Schulman, H.M., Ponka, P., EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on •OH formation by the Fenton reaction (1999) Biochim. Biophys. Acta, 1426, pp. 475-482 Hermes-Lima, M., Ponka, P., Schulman, H.M., The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate (2000) Biochim. Biophys. Acta, 1523, pp. 154-160 Hershko, C., Iron chelators (1994) Iron Metabolism in Health and Disease, pp. 391-426. , Brock, J.H., Halliday, J.W., Pippard, M.J., Powell, L.W. (Eds.). W.B. Saunders, London Itoh, H., Shioda, T., Matsura, T., Koyama, S., Nakanishi, T., Kajiyama, G., Kawasaki, T., Iron ion induces mitochondrial DNA damage in HTC rat hepatoma cell culture: Role of antioxidants in mitochondrial DNA protection from oxidative stresses (1994) Arch. Biochem. Biophys., 313, pp. 120-125 Jensen, B.D., Gunter, K.K., Gunter, T.E., The efficiencies of the component steps of oxidative phosphorylation: II. Experimental determination of the efficiencies in mitochondria and examination of the equivalence of membrane potential and pH gradient in phosphorylation (1986) Arch. Biochem. Biophys., 248, pp. 305-323 Kachur, A.V., Tuttle, S.W., Biaglow, J.E., Autoxidation of ferrous ion complexes: A method for the generation of hydroxyl radicals (1998) Radiat. Res., 50, pp. 475-482 Link, G., Konijn, A.M., Hershko, C., Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells (1999) J. Lab. Clin. Med., 133, pp. 179-188 Meneghini, R., Iron homeostasis, oxidative stress, and DNA damage (1997) Free Radical Biol. Med., 23, pp. 783-792 Minotti, G., Aust, S.D., An investigation into the mechanism of citrate-Fe 2+-dependent lipid peroxidation (1987) Free Radical Biol. Med., 3, pp. 379-387 Nair, J., Carmichael, P.L., Fernando, R.C., Phillips, D.H., Strain, A.J., Bartsch, H., Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis (1998) Cancer Epidemiol., Biomarkers Prev., 7, pp. 435-440 Richardson, D.R., Milnes, K., The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone (1997) Blood, 89, pp. 3025-3038 Richardson, D.R., Ponka, P., Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism (1998) Am. J. Hematol., 58, pp. 299-305 Richardson, D.R., Ponka, P., Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron chelating agents for the treatment of iron overload disease (1998) J. Lab. Clin. Med., 131, pp. 306-314 Santos, N.C.F., (1998) Quantificação da ação antioxidante do piridoxal isonicotinoil hidrazona (PIH) contra o estresse oxidativo induzido por íons ferro, , MSc Thesis, Universidade de Brasilia, Brazil Schulman, H.M., Hermes-Lima, M., Wang, E.M., Ponka, P., In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs (1995) Redox Rep., 1, pp. 373-378 Sheth, S., Brittenham, G.M., Genetic disorders affecting proteins of iron metabolism: Clinical implications (2000) Annu. Rev. Med., 51, pp. 443-464 Smith, K.L., Kapoor, R., Felts, P.A., Demyelination: The role of reactive oxygen and nitrogen species (1999) Brain Pathol., 9, pp. 69-92 Sookvanichsilp, N., Nakornchai, S., Weerapradist, W., Toxicological study of pyridoxal isonicotinoyl hydrazone: Acute and subchronic toxicity (1991) Drug Chem. Toxicol., 14, pp. 395-403 Stal, P., Iron as a hepatotoxin (1995) Dig. Dis., 13, pp. 205-222 Wallace, K.B., Starkov, A.A., Mitochondrial targets of drug toxicity (2000) Annu. Rev. Pharmacol. Toxicol., 40, pp. 353-388 Webb, J., Vitolo, M.L., Pyridoxal isonicotinoyl hydrazone (PIH): A promising new iron chelator (1988) Birth Defects, Orig. Art. Ser., 23 (5 B), pp. 63-70